Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Rossi

Showing results (71-80 of 186) with videos related to

Pageof 19
Sort By:
Personalized Medicine|June 22, 2018
The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'Michele Basso, Vincenzo Dadduzio, Sabrina Rossi, et al.
Genes|March 3, 2021
Two Italian Patients with <i>ELOVL4</i>-Related Neuro-Ichthyosis:  Expanding the Genotypic and Phenotypic Spectrum and Ultrastructural CharacterizationAndrea Diociaiuti, Diego Martinelli, Francesco Nicita, et al.
Human Pathology|May 24, 2015
Broadening the spectrum of SMARCB1-associated malignant tumors: a case of uterine leiomyosarcoma in a patient with schwannomatosisIrene Paganini, Roberta Sestini, Matilde Cacciatore, et al.
Cancer Cell|March 31, 2004
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancerEdgard Graner, Dan Tang, Sabrina Rossi, et al.
Journal of the Neurological Sciences|November 13, 2019
Over ten years overall survival in glioblastoma: A different disease?Elisabetta Marton, Enrico Giordan, Francesca Siddi, et al.
Future Oncology (London, England)|April 26, 2017
DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancerVincenzo Di Noia, Michele Basso, Valentina Marsico, et al.
Molecular Cancer Therapeutics|April 12, 2013
SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJMonica Brenca, Sabrina Rossi, Erica Lorenzetto, et al.
Clinical Lung Cancer|November 27, 2018
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase InhibitorsSabrina Rossi, Luca Toschi, Giovanna Finocchiaro, et al.
Endocrine-Related Cancer|January 8, 2017
Somatic mutation profiling of hobnail variant of papillary thyroid carcinomaLuca Morandi, Alberto Righi, Francesca Maletta, et al.
Medicine|May 20, 2016
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or BevacizumabMichele Basso, Vincenzo Dadduzio, Francesco Ardito, et al.
Pageof 19

Showing results (71-80 of 186) with videos related to

Sort By:
Pageof 19
Personalized Medicine|June 22, 2018
The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'Michele Basso, Vincenzo Dadduzio, Sabrina Rossi, et al.
Genes|March 3, 2021
Two Italian Patients with <i>ELOVL4</i>-Related Neuro-Ichthyosis:  Expanding the Genotypic and Phenotypic Spectrum and Ultrastructural CharacterizationAndrea Diociaiuti, Diego Martinelli, Francesco Nicita, et al.
Human Pathology|May 24, 2015
Broadening the spectrum of SMARCB1-associated malignant tumors: a case of uterine leiomyosarcoma in a patient with schwannomatosisIrene Paganini, Roberta Sestini, Matilde Cacciatore, et al.
Cancer Cell|March 31, 2004
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancerEdgard Graner, Dan Tang, Sabrina Rossi, et al.
Journal of the Neurological Sciences|November 13, 2019
Over ten years overall survival in glioblastoma: A different disease?Elisabetta Marton, Enrico Giordan, Francesca Siddi, et al.
Future Oncology (London, England)|April 26, 2017
DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancerVincenzo Di Noia, Michele Basso, Valentina Marsico, et al.
Molecular Cancer Therapeutics|April 12, 2013
SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJMonica Brenca, Sabrina Rossi, Erica Lorenzetto, et al.
Clinical Lung Cancer|November 27, 2018
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase InhibitorsSabrina Rossi, Luca Toschi, Giovanna Finocchiaro, et al.
Endocrine-Related Cancer|January 8, 2017
Somatic mutation profiling of hobnail variant of papillary thyroid carcinomaLuca Morandi, Alberto Righi, Francesca Maletta, et al.
Medicine|May 20, 2016
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or BevacizumabMichele Basso, Vincenzo Dadduzio, Francesco Ardito, et al.
Pageof 19